Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions, regardless of tumor type.
Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.
Source link aaaaa